Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss

Beyond GLP-1: New 5-In-1 Compound More Effective Than Semaglutide For Diabetes And Weight Loss

Treatment for diabetes and obesity is rapidly evolving, with multi-targeted approaches taking shape. Medications like semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, have set high benchmarks for weight loss and blood sugar management. Now, researchers are exploring compounds that work on several biological pathways simultaneously. Researchers have developed a groundbreaking ‘five-in-one’ experimental compound that has…

Read More
Popular Weight Loss Drug Ozempic Could Increase Risk Of Blindness, Study Says

Popular Weight Loss Drug Ozempic Could Increase Risk Of Blindness, Study Says

Recent studies have uncovered a frightening association between the popular diabetes and weight loss drugs, Ozempic and Wegovy, with a rare eye disorder that may cause blindness. A study, published in the medical journal JAMA Ophthalmology, reported that individuals on those drugs containing semaglutide have a much larger percentage chance of acquiring NAION, or, more…

Read More
Study Links Risk of Vision Loss to Weight Loss Drug Semaglutide, Experts Call for Monitoring – News18

    Study Links Risk of Vision Loss to Weight Loss Drug Semaglutide, Experts Call for Monitoring – News18

    There could be a potential risk of vision loss associated with the widely prescribed weight loss and anti-diabetic drug Semaglutide, a study published in the medical journal JAMA Ophthalmology has found. The study conducted by Boston-based researchers found that there is a potential risk of the development of non-arteritic ischemic optic neuropathy (NAION) associated with…

    Read More